Stay up to date with our newsletter

Get in touch!

What can we do to help?

I would like to:

Lets start the conversation!

Sign up to our newsletter

View open positions on our Careers page,
or connect with us on Linkedin Twitter Facebook Youtube

Thank you!
We will be in touch shortly.

2020.08.26

Sai Life Sciences joins the ACS Green Chemistry Institute Pharmaceutical Roundtable

ACS Green Chemistry Institute Pharmaceutical Roundtable

Sai Life Sciences today announced its induction to the ACS Green Chemistry Institute Pharmaceutical Roundtable (ACS-GCIPR) as an ‘Associate Member’. The company has been committed to increasing the adoption of Green Chemistry principles in its process development and instituted its inaugural ‘Green Chemistry Awards’ last year, to recognize and celebrate teams that make notable contributions towards greener processes. Joining the ACS-GCIPR will allow the company to interact with large pharma and other CDMOs to further share and develop best practices in Green chemistry and sustainability

Welcoming Sai Life Sciences into its fold, an ACS-GCIPR spokesperson said, “The ACS GCI Roundtable is delighted to welcome Sai Life Sciences into its membership. As one of a few CDMO companies in our membership, their enthusiasm in catalysing the integration of green chemistry and engineering in the pharmaceutical industry is another heartening sign that adoption of Green Chemistry principles is indeed gaining momentum. We look forward to their active participation in the important work of the roundtable.”

Established in 2005 by the American Chemical Society’s Green Chemistry Institute, the Pharmaceutical Roundtable’s activities are driven by the shared belief that green chemistry and engineering is imperative for business and environmental sustainability. Its member companies come together to catalyse innovative approaches to improving process efficiency and product quality through green chemistry and engineering.

Over the past 18 months, Sai Life Sciences has made several enhancements to its HSE practices as part of the org-wide transformation initiative, Sai Nxt. Earlier this year, it became the first India-headquartered company to join the PSCI membership. The company also received 5-Star rating for Excellence in EHS Practices at the Confederation of Indian Industry (CII) South awards 2019. It operates a Zero Liquid Discharge cGMP manufacturing site in Bidar, India and has achieved zero waste to landfill.

News

2020.11.20

Sai Life Sciences opens representative office in Tokyo, Japan

Sai Life Sciences opens representative office in Tokyo, Japan

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRO-CDMO), announced the opening of its representative office in Tokyo, Japan. The new office will serve as base for the company’s outreach to innovator pharmaceutical and biotech companies in Japan and other countries in the Asia Pacific region. A seasoned industry […]
Read more

2020.10.26

Biology, DMPKT & Vivarium

Sai Life Sciences to significantly expand biology capabilities at its integrated R&D campus

Commences construction of new 75,000 sq. ft. facility in Hyderabad Augmenting India team to 170 biologists Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMO), today announced plans to significantly expand its biology capabilities at its integrated R&D campus in Hyderabad, India with a dedicated 75,000 sq. ft. facility […]
Read more

2020.10.23

Green Chemistry Awards

Sai Life Sciences introduces Green Chemistry Awards

With the purpose of celebrating and recognizing teams and projects that demonstrate notable work in Green Chemistry, Sai Life Sciences instituted the ‘Green Chemistry Awards’ earlier this year. Using an internally developed computational model, projects were assessed on their ‘Greenness Index’ that is a composite of several attributes across atom & mass efficiency, e-factor, water […]
Read more

2020.10.23

ICH-M7 Services

Comprehensive ICH-M7 assessments for starting materials, intermediates, and final API

Sai Life Sciences offers comprehensive ICH-M7 services to help assess the potential risks of our customers’ starting materials, intermediates, and final API for mutagenicity assessment. As mandated in the ICH M7 guidelines, pharmaceutical companies are now required to assess, identify, and categorize their starting materials, intermediates and final API routes of synthesis and resulting impurities […]
Read more

2020.09.10

Discovery Biology Laboratory in Cambridge, MA, USA

Sai Life Sciences expands suite of cellular analysis platforms in Cambridge, MA

Sai Life Sciences today announced the addition of state-of-the-art cellular analysis platforms at its Discovery Biology facility in Cambridge, Massachusetts, USA. Coinciding with its first anniversary in Cambridge, the expanded suite of capabilities include the Opera Phenix high content screening platform, FACSCelesta flow cytometer and FACSMelody flow sorter, enabling it to better serve start-up and […]
Read more